CPHI China Pharma Holdings Inc.: Wutah pendapatan triwulanan

Simbol resmi perusahaan China Pharma Holdings, Inc. (CPHI)

Pressure from VBP government procurement and capacity upgrade costs are squeezing margins, which is evident in the quarter-over-quarter revenue growth dynamics for China Pharma Holdings (CPHI). The value of 52.10 captures the current magnitude of the indicator. The business relies on the expansion of B2B distribution for psychoneurological agents and the scaling of generics. Stability is ensured by the production of a wide range of cardiovascular and gastrointestinal drugs.

CPHI (China Pharma Holdings) riwayat Tingkat wutah dodolan sajrone kuartal saka 04.07.2022 nganti 21.11.2026

Ringkesan rincian data analitis chinapharmaholdings.com (CPHI)

Analisis umum perusahaan:CPHI - China Pharma Holdings, Inc.
Produk sing diprodhuksi China Pharma Holdings

The efficiency of China Pharma Holdings (CPHI) regional logistics hubs in drug distribution is directly reflected in sales dynamics. By analyzing the quarterly revenue growth rate, an investor assesses the percentage change in sales volume for the current period relative to the previous quarter, which reveals the actual speed of business expansion. Monitoring this chart protects against market noise by objectifying the company's growth rates relative to industry averages.